BioSpace News Archive

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology, announced that members of the senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET.

In a landmark study published in Nature Communications, researchers have discovered that caffeine is responsible for triggering a cascade effect that reduces LDL cholesterol in the blood - the so-called “bad” cholesterol.

MDxHealth SA, a commercial-stage precision diagnostics company, announced that the Company will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will be held virtually from February 15-17, 2022.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the publication of pre-clinical data demonstrating the cytotoxic potency and efficacy of NK cells precomplexed with ICE® molecules after one cycle of cryopreservation.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced its commercial launch, with the first installation in the U.S. market, of its next generation excimer laser system, XTRAC Momentum™ 1.0.

Phathom Pharmaceuticals, Inc. reported positive topline results from PHALCON-NERD, a Phase 2 study evaluating three dose levels of vonoprazan as an on-demand therapy for relief of episodic heartburn in subjects with non-erosive gastroesophageal reflux disease.

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced that it will release financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022.

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it intends to offer and sell in an underwritten public offering up to $200 million of shares of its common stock.

Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to sell Armata common stock and warrants to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc., Armata’s largest shareholder.